The Mi-2/nucleosome remodeling and deacetylase (NuRD) complex is an abundant deacetylase complex with a broad cellular and tissue distribution. It is unique in that it couples histone deacetylation and chromatin remodeling ATPase activities in the same complex. A decade of research has uncovered a number of interesting connections between Mi-2/NuRD and gene regulation. The subunit composition of the enzyme appears to vary with cell type and in response to physiologic signals within a tissue. Here, we review the known subunits of the complex, their connections to signaling networks, and their association with cancer. In addition, we propose a working model that integrates the known biochemical properties of the enzyme with emerging models on how chromatin structure and modification relate to gene activity.
Introduction
A decade ago, Schreiber and co-workers (Taunton et al., 1996) ushered in the era of molecular analysis of histone deacetylase with the biochemical identification of a mammalian protein possessing this enzymatic activity. This protein proved to be closely related to the yeast reduced potassium dependence 3 (Rpd3), a known regulator of gene expression. Subsequent studies have uncovered a family of proteins with sequence similarity to Rpd3, including HDAC1, HDAC2, HDAC3 and HDAC8 (reviewed in Grozinger and Schreiber, 2002) . The two highly related proteins HDAC1 and HDAC2 have been identified in multiple different biochemical forms. Initial reports on the biochemical association of these proteins with the Sin3a corepressor in a large protein complex strongly supported the hypothesis that these enzymes are involved in gene regulation (Grozinger and Schreiber, 2002) . Subsequent studies have revealed that the biochemistry of these proteins is somewhat complicated. In addition to the Sin3a containing complex, HDAC1 and HDAC2 are also reported to be components of another large protein complex, termed the CoREST complex (Grozinger and Schreiber, 2002) .
Approximately a decade ago, several independent research groups reported the biochemical characterization of a large macromolecular complex coupling a chromatin remodeling ATPase and HDAC1/HDAC2 (Tong et al., 1998; Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998) . This complex, Mi-2/NuRD, is the only known protein entity coupling these two independent, chromatin-directed enzymatic functions. A central question that remains unresolved is why evolution has coupled these two enzymatic functions into a single protein complex (Tyler and Kadonaga, 1999) . Here, we discuss this unique coupling of enzymatic activities along with reviewing the potential roles of the other identified subunits in the Mi-2/NuRD complex. Further, we offer a working model that assimilates the known biochemical characteristics of the complex with newly developing models relating chromatin architecture and gene activity.
Chromatin remodeling ATPase function
The ATPase activity of Mi-2/NuRD resides in one or both of the two Mi-2 proteins, a and b (also known as CHD3/CHD4). These large helicase-like ATPases contain conserved PHD fingers, chromodomains and a putative DNA-binding domain (Woodage et al., 1997) . The Mi-2 a/b proteins fall within a subclass of the SWI/ SNF family (Eisen et al., 1995) and are widely conserved throughout the animal and plant kingdoms, but are absent in yeast. ATPase activity of Mi-2 proteins from three different species (Drosophila melanogaster, Xenopus laevis and Homo sapiens) is stimulated by chromatin, but not by free DNA or by histones (Wade et al., 1998; Brehm et al., 2000; Wang and Zhang, 2001 ).
The human Mi-2 proteins were initially discovered as autoantigens in the connective tissue disease dermatomyositis (Ge et al., 1995; Seelig et al., 1995) . Approximately 25% of dermatomyositis patients exhibit anti-Mi-2 antibodies; the development of these autoantibodies appears to be largely restricted to this disease (reviewed in Callen and Wortmann, 2006) . There is a definitive relationship between dermatomyositis and cancer, with roughly 20-25% of patients eventually developing malignancy (Callen and Wortmann, 2006) . The greatest risk areas for these patients are cancers of the ovary, lung, pancreas, stomach, colon/rectum and lymphomas (Hill et al., 2001) . Prevailing models describe dermatomyositis as a paraneoplastic disease, with major differences in the clinical presentation of patients who have both malignancy and dermatomyositis as compared to patients with dermatomyositis alone (Hill et al., 2001) . The relationship between presence of anti-Mi-2 antibodies and development of malignancy remains unclear.
The conserved Mi-2 proteins are known to be involved in response to cell signaling events in various model organisms. In Caenorhabditis elegans, the two Mi-2 homologs play a crucial role in a Ras signaling pathway critical to cell fate determination during hermaphrodite development (von Zelewsky et al., 2000) . The Arabidopsis Pickle gene, another Mi-2 homolog, acts as a component of an auxin signaling pathway required for lateral root formation (Fukaki et al., 2006) . These examples suggest that mammalian Mi-2 proteins will also be important components of developmental signaling pathways, potentially with cancer relevance. However, the lack of genetic models in mammals has hampered progress in this area. A mouse model has been created for analysis of CHD4 and utilized to study genetic roles of this factor in Tlymphocyte development. In knockout animals, levels of CHD3 are increased in the thymus, and various defects in T-lymphocyte development and differentiation are impacted (Williams et al., 2004) . The future use of this and similar mouse models will provide information on the genetic requirement(s) for different forms of Mi-2 in the developing mammalian embryo.
Protein deacetylase function
The catalytic deacetylase subunits of Mi-2/NuRD are composed of HDAC1 and/or HDAC2. These proteins are highly conserved and are present in all eukaryotes. Both the genetic and the biochemical properties of these notable factors make teasing out functions specific to Mi-2/NuRD complicated. In mammals, HDAC1 action is known to be critical to normal control of the cell cycle through direct interaction with the Rb tumor suppressor (Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . Targeted disruption of mouse HDAC1 results in embryonic lethality with multiple defects in expression of regulators of the cell cycle (Lagger et al., 2002) . These data suggest a critical role for histone deacetylation and for HDAC1 in particular in cell-cycle progression. The connections to Rb strongly suggest that HDAC1 and/or HDAC2 may play a key role in cell cycle checkpoints whose disruption is integral to the process of malignant transformation.
The known biochemistry of HDAC1 and HDAC2 suggests that interpretation of genetic data is not straightforward. In addition to being integral subunits of Mi-2/NuRD (Tong et al., 1998; Wade et al., 1998; Xue et al., 1998; Zhang et al., 1998) , HDAC1 and HDAC2 are also found in association with corepressor complexes containing CoREST (Humphrey et al., 2001) and mSin3a Nagy et al., 1997; Zhang et al., 1997) . Further, in some instances these proteins are also believed to function without additional biochemical partners. Deciphering precisely which complex might be impacted by genetic deletion of HDAC1 will have to await further genetic analysis of a subset of the many nuclear proteins which have been identified as interaction partners.
Interestingly, Zhang et al. (1999) , have observed that components of the Mi-2/NuRD complex had a stimulatory impact on deacetylase activity of recombinant HDAC1/HDAC2. While the precise basis of this finding remains unknown, it is tempting to speculate that association with partner proteins either stabilizes a critical structure within the HDAC proteins, or participates in the stable association of the enzymes with their substrates.
Connections to DNA methylation
In addition to the two subunits with enzymatic activity, the Mi-2/NuRD complex contains several other proteins of importance. The smallest subunit is a member of the methyl CpG-binding domain (MBD) family of proteins (Wade et al., 1999; Zhang et al., 1999) . The MBD subunit, like all other known subunits of the complex, is an interchangeable component varying between the family members MBD2 and MBD3 (Le Guezennec et al., 2006) . One of these two proteins, MBD2, has the capacity to selectively recognize methylated DNA (Hendrich and Bird, 1998) . The other, MBD3, has apparently lost this function during vertebrate evolution (Hendrich and Tweedie, 2003) owing to a critical amino acid change in the MBD fold (Saito and Ishikawa, 2002; Fraga et al., 2003) .
Initial descriptions of Mi-2/NuRD were unclear on whether MBD2 was, in fact, a bona fide subunit of the complex or could merely associate with the complex in solution (Wade et al., 1999; Zhang et al., 1999) . However, subsequent analysis has left little doubt that MBD2, like MBD3, is biochemically linked to the other subunits of Mi-2/NuRD. Several groups have since described the biochemical identification of both MBD2 and MBD3 containing forms of the complex (Feng and Zhang, 2001; Le Guezennec et al., 2006) , and a direct interaction between MBD2 and p66, another component of the Mi-2/NuRD complex, has been documented (Brackertz et al., 2002 (Brackertz et al., , 2006 . These experiments have served to clarify the relationship between Mi-2/NuRD and the MBD family, indicating that MBD2 and MBD3 are alternative subunits. However, the biological ramifications of differential inclusion remain elusive. Mouse genetics on the MBD protein family has made impressive contributions to this field in recent years. Mutation of MBD2 has moderate phenotypic consequences on normal development while mutation of MBD3 results in embryonic lethality (Hendrich et al., 2001) . Importantly, there is evidence for genetic interactions between MBD2 and MBD3 (Hendrich et al., 2001) , supporting the contention that they constitute alternative subunits of Mi-2/NuRD. Recent analysis of MBD3 mutant ES cells and embryos (Kaji et al., 2006 (Kaji et al., , 2007 has indicated a role for MBD3 in the development of pluripotency. While it seems clear that MBD3 is required for critical gene regulatory events during development, it remains unclear to what extent Mi-2/NuRD participates in establishment or maintenance of transcriptional repression at regions of the genome where DNA is highly methylated.
Retinoblastoma associated proteins and p66
An additional subunit of the complex consists of RbA p46 and/or RbA p48 (Zhang et al., 1999) , now termed Rbbp4 (p48) and Rbbp7 (p46). These proteins were originally identified based on their interaction with the Rb tumor suppressor protein (Qian et al., 1993) . They contain a number of WD repeats, a sequence motif that forms the basis for the b-propeller structure of the b-subunit of the G protein transducin (Sondek et al., 1996) . These two proteins are presumed to be structural subunits of Mi-2/NuRD, with the potential for different blades of the propeller structure to act as protein interaction surfaces (Marhold et al., 2004) . Interestingly, p46 and p48 have been shown to be components of several other multiprotein chromatin modification complexes in which they interact directly with core histones (reviewed in Loyola and Almouzni, 2004) .
Some versions of the complex are also thought to incorporate a second structural and/or regulatory subunit, p66a or p66b (Wade et al., 1999; Brackertz et al., 2002; Feng et al., 2002 ) also known as Gatad2a (p66) and Gatad2b (p68). As mentioned above, the p66 subunits interact with the MBD2 subunit and may be involved in interactions of the complex with methylated DNA (Feng and Zhang, 2001; Brackertz et al., 2006) . Like the RbA p46/48 subunits, both p66 isoforms have the capacity to interact directly with core histones (Brackertz et al., 2006) .
There is a single homolog of the mammalian p66 subunits in Drosophila. This gene has been identified by Nusse and co-workers (Kon et al., 2005) as a component of the Wnt signaling pathway in flies. The gene is essential and mutant animals die during development, probably owing to misregulation of the ecdysone response (Kon et al., 2005) , a developmental signaling pathway also connected to the Drosophila homolog of MBD2/3 (Ballestar et al., 2001) . It is unknown whether mammalian p66 homologs are also required for normal development and whether they play a fundamental role in steroid signaling.
MTA proteins and connections to metastasis
The final characterized subunit of the Mi-2/NuRD complex consists of the metastasis associated (MTA) protein family (for recent reviews, see Bowen et al., 2004 and Manavathi and Kumar, 2007) . The founding member of this family, MTA1, was originally isolated based on its differential expression in a model for metastatic growth (Pencil et al., 1993) . Whether other members of the family have any role in cancer metastasis is unknown; likewise, the functional role of MTA proteins in the Mi-2/NuRD complex remains unknown. However, it is clear that these proteins have meaningful connections to transcriptional regulation. All three members of the MTA family have been demonstrated to be components of Mi-2/NuRD (Xue et al., 1998; Zhang et al., 1999; Fujita et al., 2003) . It has been suggested, on the basis of phylogenetic comparisons, that the MTA family underwent repeated duplication to produce the three loci present in vertebrate genomes (Bowen et al., 2004) . The vertebrate MTA2 protein is more closely related to the ancestral MTA protein than either MTA1 or MTA3, supporting the hypothesis that these MTA proteins evolved to perform cell-type specific functions in the vertebrate lineage (Bowen et al., 2004) .
The MTA family is intimately connected to the biology of the estrogen receptor (ER) (Kumar, 2003; Cui et al., 2006) in breast cancer and to mammary gland biology (Manavathi and Kumar, 2007) . Two MTA proteins interact directly with the ER itself. MTA1s, a splice variant of MTA1, has been implicated in sequestering the ER in the cytoplasm (Kumar et al., 2002) . Both MTA1 and MTA2 have been identified in the nucleus as corepressors of estrogen action. MTA1, in a pathway downstream of heregulin signaling, blocks the ability of estradiol to activate genes through the ER in an HDAC-dependent manner (Mazumdar et al., 2001) . MTA2, on the other hand, can render breast cancer cells insensitive to both estrogen and tamoxifen, possibly through deacetylation of the ER itself (Cui et al., 2006) .
The final member of this family, MTA3, has been studied in some detail at the molecular level. MTA3 abundance correlates with the presence of ER-a in breast cancer cell lines (Fujita et al., 2003) . This correlation results from direct activation of the MTA3 promoter by ER-a Mishra et al., 2004) . Significantly, in the context of cultured breast cancer cells, MTA3 serves to repress transcription of genes implicated in invasive growth, such as the transcription factor Snail (Fujita et al., 2003) . These findings are supported by analysis of expression microarray data sets derived from human breast tumors which confirm the relationships observed in transformed cells (Fujita et al., 2003) .
In a transgenic mouse model, MTA3 has been implicated in suppression of ductal branching and morphogenesis in the mammary gland, potentially related to repression of Wnt4 signaling (Zhang et al., 2006) . In contrast, a transgenic mouse expressing MTA1 exhibits diametrically opposed phenotypes, with more elaborate ductal branching (Bagheri-Yarmand et al., 2004) . These findings indicate that different members of the MTA family can direct the Mi-2/NuRD complex to perform unique functions within a given cell or tissue in vivo.
Mind the gap?
While we know that the Mi-2/NuRD complex has an important role in modifying gene expression, we are still discerning what steps in chromatin alteration and remodeling are linked to the complex. Along these lines, we are also learning more about how genes in general are activated or repressed and the chromatin organization associated with these different states. The emergence of DNA microarray technology and linked techniques for high-resolution mapping of nucleosome positions and histone modifications has revolutionized how we think about chromatin organization and the information content of chromosomes. We now know that active genes are enriched for a variety of histone marks, particularly high levels of histone acetylation, at or near promoter regions (Kurdistani et al., 2004; Schubeler et al., 2004; Bernstein et al., 2005; Pokholok et al., 2005) . Another important emerging feature of active genes, predicted from previous studies (Reinke and Horz, 2003; Boeger et al., 2004) , is the presence at the promoters of a nucleosome-free region of variable size (Yuan et al., 2005; Heintzman et al., 2007) . While this is still an emerging area, current models (see Figure 1 ) depict the process of gene activation as one in which a host of histone modifications, including acetylation, are enriched at actively transcribing promoters. Further, chromatin organization is relaxed, with decreased nucleosome density and the presence of a prominent, nucleosome-free region immediately encompassing the transcription start site.
Repressed genes have many of the opposite characteristics including high nucleosome density and markedly different histone modifications (Schubeler et al., 2004; Bernstein et al., 2005; Pokholok et al., 2005) . Interestingly, genes with low or undetectable levels of transcription lack the nucleosome-free region at the transcription start site characteristic of many active loci (Heintzman et al., 2007) .
We are still trying to decipher how cells convert the active chromatin pattern into that of a repressed gene with low levels of transcription (see Figure 1) . The Mi-2/ NuRD complex has the necessary attributes to catalyse conversion of an active, hyperacetylated promoter to that of an inactive gene. The Mi-2 ATPase is known to facilitate nucleosome mobility through a sliding mechanism (Brehm et al., 2000; Guschin et al., 2000) . Histone deacetylation, in turn, would be catalysed by the activity of HDAC1/2. The net result of the combined activity of these two enzymatic moieties would result in the generation of densely packed, hypoacetylated nucleosomes.
Are loss of acetylation and the creation of closely packed nucleosomes sufficient to result in a chromatin state refractory to the transcription apparatus, or are other enzymatic actions required? The answer to this question remains unknown as the kinetics of change in nucleosome positioning and modification accompanying transcriptional repression events remains understudied. Limited evidence suggests that such events might be a component of stable repression (Metivier et al., 2003) , but seems to indicate they are not sufficient.
What's next?
The field of chromatin-mediated control of gene activity has blossomed over the past decade. The importance of enzymatic events leading to dynamic behavior of histone modifications and nucleosome positioning in gene regulation has gained widespread acceptance. The Mi-2/ NuRD complex is abundant in mammalian cells, has a widespread tissue distribution and possesses enzymatic functions central to chromatin based gene regulation. It is increasingly clear that the functions of this enzyme will prove important in normal development and in pathology.
Current challenges include the lingering question of why evolution couples two distinct activities into a single protein machine. Is the answer related to nucleosomefree regions at active promoters, or to another biological issue altogether? How is the complex recruited to distinct regions of the genome? What is the relationship of the complex to DNA methylation? Is transcriptional regulation the only function of the enzyme or does it also play a key role in other nuclear processes such as chromosome replication or repair? Exciting discoveries undoubtedly lie ahead with much left to learn about this multifaceted, dual-enzymatic macromolecule with such apparent importance in chromatin regulation. The human Mi-2/NuRD complex SA Denslow and PA Wade
